SCHEMBL26260061

SCHEMBL26260061

COc1ccc2c(-c3cccnc3)c(OC)cc(-c3cccnc3)c2c1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 1/20 0.57
▸ ALDH1A1 P00352 1/20 0.57
▸ HPGD P15428 1/20 0.57
▸ HSD17B10 Q99714 1/20 0.57
▸ CYP11B2 P19099 12/20 0.56
▸ CYP11B1 P15538 11/20 0.56
▸ CYP17A1 P05093 5/20 0.56
▸ CYP3A4 P08684 3/20 0.56
▸ CYP19A1 P11511 3/20 0.51
▸ CYP1A2 P05177 2/20 0.49
▸ CYP1A1 P04798 1/20 0.49
▸ CYP1B1 Q16678 1/20 0.49
▸ PDE10A Q9Y233 1/20 0.48
▸ CYP2C9 P11712 2/20 0.47
▸ NPC1 O15118 2/20 0.47
▸ RAB9A P51151 1/20 0.47
▸ CYP2D6 P10635 1/20 0.47
▸ CYP2C19 P33261 1/20 0.47
▸ CLK4 Q9HAZ1 1/20 0.47
▸ MKNK1 Q9BUB5 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26260037 0.82 CYP11B1 (0.53) KDM4EALDH1A1HPGDHSD17B10CYP11B2
SCHEMBL26259504 0.81 MAPK13 (0.46) KDM4EALDH1A1HPGDHSD17B10CYP11B2
SCHEMBL26259484 0.80 KDM4E (0.51) KDM4EALDH1A1HPGDHSD17B10CYP3A4
SCHEMBL26260092 0.80 NPC1 (0.60) KDM4EALDH1A1HSD17B10CYP11B2CYP11B1
SCHEMBL29775388 0.79 CYP11B2 (0.61) KDM4EALDH1A1HPGDHSD17B10CYP11B2
SCHEMBL8165131 0.79 CYP11B2 (0.61) KDM4EALDH1A1HPGDHSD17B10CYP11B2
SCHEMBL14925557 0.76 CYP11B2 (0.74) KDM4EALDH1A1HPGDHSD17B10CYP11B2
SCHEMBL26260045 0.74 MAOB (0.46) CYP3A4CYP1A2CYP1A1CYP1B1CYP2C9
SCHEMBL28225240 0.74 MKNK1 (0.60) KDM4EHSD17B10CYP11B2CYP11B1CYP17A1
SCHEMBL16446303 0.73 CYP11B2 (0.74) KDM4EALDH1A1HPGDHSD17B10CYP11B2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230287262-A1 PHOTON UPCONVERSION COMPOSITION, FILM, METHOD FOR CONVERTING VISIBLE LIGHT INTO ULTRAVIOLET LIGHT, AND COMPOUND KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION (JP) 2023-09-14 — — US disclosed
US-20230287262-A1 PHOTON UPCONVERSION COMPOSITION, FILM, METHOD FOR CONVERTING VISIBLE LIGHT INTO ULTRAVIOLET LIGHT, AND COMPOUND KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION (JP) 2023-09-14 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230287262-A1 PHOTON UPCONVERSION COMPOSITION, FILM, METHOD FOR CONVERTING VISIBLE LIGHT INTO ULTRAVIOLET LIGHT, AND COMPOUND NUDC, CCNL2, SPIN3 KDM4E 1663/4885ALDH1A1 2125/4885HPGD 3758/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback